Tag:

Janssen

Latest Headlines

Latest Headlines

Janssen's new Prezcobix push urges HIV patients to share pics with their docs

Say cheese, bus shelter ad. Janssen's Prezcobix campaign advocates a new way for potential patients to talk to their doctors: Snap a picture and share it.

HK-based Hutchison MediPharma sees Janssen exit from HMPL-507 candidate alliance

An exit by Janssen Pharmaceuticals from a seven year alliance with Hutchison MediPharma (HMP) to develop a novel inflammation/immunology candidate, HMPL-507, will see the HK-based firm carry-on independently, according to a press release.

Biopharma's 10 highest-paid heads of R&D

The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.

SC high court cuts J&J's Risperdal marketing penalty back again, to $124M

South Carolina's Supreme Court further cut the penalty against Johnson & Johnson stemming from a Risperdal deceptive-marketing lawsuit. Originally ordered to pay $327 million for violations of the state's Unfair Trade Practices Act, J&J's Janssen Pharmaceutica unit now faces a $124 million judgment.

J&J's HIV vaccine shows promise in monkeys; PhI/IIa to start soon

The search for an HIV vaccine has been long and difficult, but researchers from Johnson & Johnson, Harvard and other groups may have made a leap. J&J's Janssen reported encouraging results Thursday from its preclinical trial of an HIV vaccine in rhesus monkeys. Encouraging enough for the company to sponsor human studies--the first time a Big Pharma is doing so in the HIV space.

HIV investigators at Harvard, J&J see promise in early-stage vaccine

A team of collaborators drawn from Harvard, Johnson & Johnson and other groups published results from a preclinical animal study Thursday afternoon that underscores the potential for developing the world's first HIV vaccine.

J&J recalls contraceptives for subpotency

J&J's Janssen unit is recalling one lot of Ortho-Cept tablets because of the potential that the potency of the two active ingredients may not meet specifications, Health Canada reports.

Janssen looks to Ichor's electroporation delivery system for hep B jab

San Diego biotech Ichor Medical Systems stands to earn up to $85 million, plus royalties, if its new partnership with Johnson & Johnson's Janssen hits the right notes. The companies announced plans this week to develop DNA vaccines for hepatitis B using Ichor's TriGrid electroporation technology for clinical administration.

Depomed picks up loan for second half of $1.05B Nucynta acquisition from J&J

After securing U.S. rights to Janssen's Nucynta franchise in mid-January this year, Depomed has now raised enough to pay for it in full. Nucynta fits nicely into Depomed's cadre of pain and neurological treatments, and the Newark, CA-based company's Acuform drug delivery tech already gives Nucynta an edge as an oral treatment.

UPDATED: NIH funds studies of J&J's and GSK's injectable HIV meds, says daily pills lead to noncompliance

In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.